Dr. Jocelyn Wittstein

And then, you know, the other thing is when you look at our confidence intervals, they didn't overlap.

So, you know, if we could have just had some more patients, I think we would get there.

And I mean, just the number of cases of frozen shoulder in the hormone therapy group were so small.

But again, you know, we need larger numbers.

So I did a post hoc power analysis, you know, and I know how many we need, but I can't go back and get more because this was, it had to be, I used patients that were in an enclosed system, meaning they were within our HMO.

So there's not leakage, I'm not missing data.

But I have ongoing pro...

Perspective.

Perspective work that I do with our women's health group.

We enroll people in something called our musculoskeletal symptoms of menopause registry.

We survey them every few months, follow them with timing of onset of hormone therapy or not.

So we're doing that prospectively.

And I have a very large cross-sectional study that we'll be coming out with that I actually collaborated with Vanda Wright on in terms of distributing.

And that was great that she was able to collaborate with us.

And we have huge numbers and we'll be coming out with that.

And I don't want to say what it shows yet, but it does confirm our suspicions.

I have that in submission.

And so I think it's becoming more and more obvious and people are recognizing this more and more.

I remember that.

And so many people reached out to me.